TNGX - CIK 0001819133
The table below shows Tango Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$138.89M | -$131.50M | -$117.98M | -$109.08M | -$59.53M | $70.07M |
| Capital expenditure | $1.05M | $754.00K | $1.53M | $7.69M | $1.84M | $1.11M |
| Investing cash flow | -$40.87M | $86.13M | $41.43M | $26.40M | -$183.43M | -$145.47M |
| Dividends paid | - | - | - | - | - |
Tango Therapeutics, Inc. reported operating cash flow of -$138.89M for fiscal year 2025. That is down 5.6% from -$131.50M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from $70.07M (FY 2020) to -$138.89M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $222.50M | $47.66M | $82.41M | $1.61M | $357.32M | $80.88M |